Vietnam's Prime Minister has issued Decision No. 1165/QD-TTg, approving the National Strategy for Development of Vietnam’s Pharmaceutical Industry to 2030, with a long-term vision extending to 2045. This strategic roadmap aims to position Vietnam as a regional hub for pharmaceutical manufacturing, research, and innovation, driven by expanding healthcare spending and a growing middle class.

The strategy outlines core objectives including ensuring affordable access to essential medicines, enhancing domestic research capabilities for original brand-name drugs, and elevating the pharmaceutical regulatory system to WHO Maturity Level 4. It emphasizes sustainable exploitation of medicinal herbs, production of high-value goods from natural extracts, and optimization of medication use across the supply chain. These goals align directly with B2B priorities in pharmaceutical outsourcing, contract manufacturing, and regulatory compliance, creating opportunities for international CROs, CMOs, and technology providers.

Specific targets are ambitious and measurable. By 2030, Vietnam plans to achieve 100% proactive supply of drugs for disease prevention and treatment, manufacture 80% of domestically consumed drugs accounting for 70% of market value, and produce 20% of required raw materials locally. Vaccine production will meet 100% of expanded immunization needs and 30% of service vaccination demands. The strategy mandates development of at least 100 original brand-name drugs, vaccines, or biological products, alongside designating eight areas for sustainable medicinal herb exploitation and 2-5 large-scale production zones.

Regulatory enhancements are central, with goals to reach WHO Maturity Level 3 or higher, ensure 100% of drug trading establishments meet good practice standards, and have all testing facilities comply with GLP. At least 20% of manufacturing sites will adhere to EU-GMP or PIC/S-GMP equivalents. Full monitoring of drug effectiveness and safety, digital transformation of the entire industry, and AI deployment in operations are prioritized. Interconnectivity across manufacturing, wholesale, import-export, and retail establishments will reach 100%, supported by a centralized Pharmaceutical Industry Data Bank.

Foreign investment and partnerships are pivotal. Vietnam seeks collaboration with multinational corporations for R&D, technology transfers, and capacity building in pharmaceutical management. The EU-Vietnam Free Trade Agreement (EVFTA) has eliminated over half of tariffs on EU pharma imports, enabling 100% foreign-owned import and distribution entities. This opens doors for European firms in active pharmaceutical ingredients (APIs), excipients, formulations, and advanced manufacturing equipment.

Workforce development targets a 4:10,000 pharmacist-to-population ratio, with 20% trained in clinical pharmacy. Funding will combine state resources, international donors like WHO, and private investments from domestic and foreign businesses. The projected industry value of US$20 billion by 2045 underscores massive growth potential in contract services, supply chain solutions, and cleanroom technologies.

For pharmaceutical executives and R&D heads, this strategy signals strategic entry points in Vietnam's market. Procurement professionals can anticipate demands for laboratory instrumentation, process machinery, and quality assurance systems. CRO/CMO leaders will find opportunities in clinical trials outsourcing and biologics development. Regulatory teams must note evolving compliance landscapes, while technology vendors can target digital transformation and AI integrations.

Challenges include standardizing medicinal ingredients like extracts and powders, scaling raw material production, and achieving GMP standards amid rapid expansion. Success hinges on government guidance and foreign expertise in areas like pharmaceutical materials handling, packaging machinery, and validation services. Vietnam's pharma evolution promises to reshape Asian supply chains, fostering partnerships that drive efficiency and innovation across the region.

The strategy's emphasis on economic and regional development positions Vietnam competitively against neighbors like India and China. Manufacturing managers should monitor infrastructure projects for cleanroom installations and cold chain logistics. Leadership changes in state agencies may accelerate implementation, offering agile players first-mover advantages in this high-growth market.